OS Therapies Incorporated

Day range

$1.21 – $1.28

Open

$1.27

Prev close

$1.30

Volume

321.73K

Market cap

$58.04M

Shares out

4.59M

P/E

—

P/S

—

P/B

-4.87

P/FCF

—

ROE

330.4%

ROA

-397.8%

Debt/Equity

-0.01

Div yield

0.00%

As of Oct 30, 2026

• Warrant or conversionOct 19, 2026

  On October 15, 2026, the Company completed an initial Closing of the Inducement Offer, at which seven Holders exercised, or pre-funded the exercise of, Existing Warrants to purchase an aggregate of 5,517,253 shares of the Company's common stock and, in exchange, the Company issued to such Holders New Warrants to purchase up to an aggregate of 5,517,253 shares of the Company's common stock.

• Executive compensation changeOct 5, 2026

  In connection with Mr. Clem's appointment as Chief Commercial Officer, the Company entered into an employment agreement with Mr. Clem setting forth the terms of his employment and initial compensation.

• Annual meeting resultsSep 9, 2026

  The stockholders ratified the appointment of MaloneBailey, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, which required the affirmative vote of the majority of shares of stock present, in person or by proxy, and entitled to vote.

• Underwriting agreementAug 21, 2026

  On August 21, 2026, OS Therapies Incorporated (the "Company") entered into an Open Market Sale Agreement℠ (the "Sales Agreement") with Jefferies LLC (the "Sales Agent"), pursuant to which the Company may offer and sell shares of its common stock from time to time through or to the Sales Agent in connection with the Company's "at the market offering" program (the "ATM Offering").

• Debt issuanceAug 12, 2026

  senior secured convertible promissory notes in an aggregate subscription amount of up to $10,000,000... The Notes bear interest at a rate of 9.0% per annum... Each tranche of the Note matures on the date that is nine months following the applicable advance date.

Days to cover

2.9

Short interest

2.82M

Avg volume

963.53K

As of Oct 15, 2026 · reported to FINRA twice monthly.

• The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology
  positiveGlobeNewswire Inc.· Mar 19, 2026
• Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities
  positiveBenzinga· Jul 16, 2025
• The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?
  positiveBenzinga· Jun 26, 2025